KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease

Epigenomics

Volumn 7, Issue 4, 2015, Pages 609-626

  Maes, Tamara ^a   Mascaró, Cristina ^a   Ortega, Alberto ^a   Lunardi, Serena ^a   Ciceri, Filippo ^a   P Somervaille, Tim C ^b   Buesa, Carlos ^a  

^a ORYZON GENOMICS   (Spain)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

acute myeloid leukemia; Alzheimer's disease; GSK2879552; histone lysine demethylases (KDMs); Huntington's disease; oncology; ORY 1001; ORY 2001; SCLC

Indexed keywords

ENZYME INHIBITOR; KDM1 INHIBITOR; UNCLASSIFIED DRUG; HISTONE DEMETHYLASE; KDM1A PROTEIN, HUMAN;

BRAIN DISEASE; BRAIN FUNCTION; COGNITION; DEGENERATIVE DISEASE; EPILEPSY; GENETIC TRANSCRIPTION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HISTONE METHYLATION; HUMAN; HUNTINGTON CHOREA; MEMORY; NEOPLASM; NONHUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETT SYNDROME; REVIEW; SCHIZOPHRENIA; SOLID TUMOR; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; NEOPLASMS; NEURODEGENERATIVE DISEASES;

AMINO ACID SEQUENCE; ANIMALS; EPIGENESIS, GENETIC; GENETIC THERAPY; HISTONE DEMETHYLASES; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84933501651     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.9     Document Type: Review

References (121)

1. Shi Y, Lan F, Matson C et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941-953 (2004).
2. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13(6), 563-567 (2006).
3. Schmidt DM, McCafferty DG. Trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46(14), 4408-4416 (2007).
4. Zhang Q, Qi S, Xu M et al. Structure-function analysis reveals a novel mechanism for regulation of histone demethylase LSD2/AOF1/KDM1b. Cell Res. 23(2), 225-241 (2013).
5. Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A. Human histone demethylase LSD1 reads the histone code. J. Biol. Chem. 280(50), 41360-41365 (2005).
6. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395, 917-921 (1998).
7. Hakimi MA, Bochar DA, Chenoweth J et al. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc. Natl Acad. Sci. USA 99, 7420-7425 (2002).
8. Hakimi MA, Dong Y, Lane WS, Speicher DW, Shiekhattar R. A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J. Biol. Chem. 278, 7234-7239 (2003).
9. Humphrey GW, Wang Y, Russanova VR et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/Kiaa0071 and Mta-L1. J. Biol. Chem. 276, 6817-6824 (2001).
10. Shi YJ, Sawada J-I, Sui GC et al. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422, 735-738 (2003).
11. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for RCOR1 in nucleosomal histone 3 lysine 4 demethylation. Nature 437(7057), 432-435 (2005).
12. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19(6), 857-864 (2005).
13. Yang M, Gocke CB, Luo X et al. Structural basis for RCOR1-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Mol. Cell 23(3), 377-387 (2006).
14. Whyte WA, Bilodeau S, Orlando DA et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482(7384), 221-225 (2012).
15. Yokoyama A, Takezawa S, Schüle R, Kitagawa H, Kato S. Transrepressive function of TLX requires the histone demethylase LSD1. Mol. Cell Biol. 28(12), 3995-4003 (2008).
16. Banck MS, Li S, Nishio H, Wang C, Beutler AS, Walsh MJ. The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics 4(2), 100-106 (2009).
17. Gocke CB, Yu H. ZNF198 stabilizes the LSD1-CoRESTHDAC1 complex on chromatin through its MYM-type zinc fingers. PLoS ONE 3(9), e3255 (2008).
18. Huang J, Sengupta R, Espejo AB et al. p53 is regulated by the lysine demethylase LSD1. Nature 449(7158), 105-108 (2007).
19. Hu X, Li X, Valverde K et al. LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis. Proc. Natl Acad. Sci. USA 106(25), 10141-10146 (2009).
20. Lin Y, Wu Y, Li J et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 29(11), 1803-1816 (2010).
21. Saleque S, Kim J, Rooke HM, Orkin SH. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol. Cell 7(4), 562-72 (2007).
22. Metzger E, Wissmann M, Yin N et al. LSD1 demethylates repressive histone marks to promote androgen-receptordependent transcription. Nature 437(7057), 436-439 (2005).
23. Culhane JC, Wang D, Yen PM, Cole PA. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J. Am. Chem. Soc. 132(9), 3164-3176 (2010).
24. Wissmann M, Yin N, Müller JM et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9(3), 347-353 (2007).
25. Liang Y, Vogel JL, Narayanan A, Peng H, Kristie TM. Inhibition of the histone demethylase LSD1 blocks alpha herpesvirus lytic replication and reactivation from latency. Nat. Med. (11), 1312-1317 (2009).
26. Liang Y, Quenelle D, Vogel JL, Mascaro C, Ortega A, Kristie TM. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 4(1) e00558-12 (2013).
27. Musri MM, Carmona MC, Hanzu FA, Kaliman P, Gomis R, Párrizas M. Histone demethylase LSD1 regulates adipogenesis. J. Biol. Chem. 285(39), 30034-30041 (2010).
28. Wang J, Scully K, Zhu X et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446(7138), 882-887 (2007).
29. Ciccone DN, Su H, Hevi S et al. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature 461, 415-418 (2009).
30. Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Res. Treat. 146(1), 99-108 (2014).
31. Fang R, Barbera AJ, Xu Y et al. Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol. Cell 39(2), 222-233 (2010).
32. Karytinos A, Forneris F, Profumo A et al. A novel mammalian flavin-dependent histone demethylase. J. Biol. Chem. 284(26), 17775-17782 (2009).
33. Chen F, Yang H, Dong Z et al. Structural insight into substrate recognition by histone demethylase LSD2/KDM1b. Cell Res. 23(2), 306-309 (2013).
34. Fang R, Chen F, Dong Z et al. LSD2/KDM1B and its cofactor NPAC/GLYR1 endow a structural and molecular model for regulation of H3K4 demethylation. Mol. Cell 49(3), 558-570 (2013).
35. Yang Z, Jiang J, Stewart DM et al. AOF1 is a histone H3K4 demethylase possessing demethylase activity-independent repression function. Cell Res. 20(3), 276-287 (2010).
36. van Essen D, Zhu Y, Saccani S. A feed-forward circuit controlling inducible NF-?B target gene activation by promoter histone demethylation. Mol. Cell 39(5), 750-760 (2010).
37. Kontaki H, Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol. Cell 39(1), 152-160 (2010).
38. Wang J, Hevi S, Kurash JK et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41(1), 125-129 (2009).
39. Jin L, Hanigan CL, Wu Y et al. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53-and DNMT1(DNA methyltransferase 1)-independent manner. Biochem. J. 449(2), 459-468 (2013).
40. Sprüssel A, Schulte JH, Weber S et al. Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia 26(9), 2039-2051 (2012).
41. Nguyen AT, He J, Taranova O, Zhang Y. Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res. 21(9), 1370-1373 (2011).
42. Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia 28(1), 44-49 (2014).
43. Wilting RH, Yanover E, Heideman MR et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 29(15), 2586-2597 (2010).
44. Rodriguez RM, Suarez-Alvarez B, Salvanés R et al. Role of BRD4 in hematopoietic differentiation of embryonic stem cells. Epigenetics 9(4), 566-578 (2014).
45. Saleque S, Cameron S, Orkin SH. The zinc-finger protooncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages. Genes Dev. 16(3), 301-306 (2002).
46. Laurent B, Randrianarison-Huetz V, Kadri Z, Romeó PH, Porteu F, Duménil D. Gfi-1B promoter remains associated with active chromatin marks throughout erythroid differentiation of human primary progenitor cells. Stem Cells 27(9), 2153-2162 (2009).
47. Lin XM, Zhong WT, Wang CL, Wang SQ. Expression of histone demethylase lysine specific demethylase 1 in acute leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 19(6), 1348-1352 (2011).
48. Harris WJ, Huang X, Lynch JT et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21(4), 473-487 (2012).
49. Binda C, Valente S, Romanenghi M et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132(19), 6827-6833 (2010).
50. Schenk T, Chen WC, Göllner S et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-transretinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18(4), 605-611 (2012).
51. Bash RO, Hall S, Timmons CF et al. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study. Blood 86(2), 666-676 (1995).
52. Li Y, Deng C, Hu X et al. Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis. Oncogene 31(48), 5007-5018 (2012).
53. Weng AP, Ferrando AA, Lee W et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
54. Yatim A, Benne C, Sobhian B et al. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol. Cell 48(3), 445-458 (2012).
55. Mulligan P, Yang F, Di Stefano L et al. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol. Cell 42(5), 689-699 (2011).
56. Su ST, Ying HY, Chiu YK, Lin FR, Chen MY, Lin KI. Involvement of histone demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell differentiation. Mol. Cell Biol. 29(6), 1421-1431 (2009).
57. Lim S, Janzer A, Becker A et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (3), 512-520 (2010).
58. Zhao ZK, Yu HF, Wang DR et al. Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. World J. Gastroenterol. 18(45), 6651-6656 (2012).
59. Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R. Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin. Pathol. 12-13 (2012).
60. Jie D, Zhongmin Z, Guoqing L et al. Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig. Dis. Sci. 58(6), 1581-1589 (2013).
61. Yu Y, Wang B, Zhang K et al. High expression of lysinespecific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma. Biochem. Biophys. Res. Commun. 437(2), 192-198 (2013).
62. Ding J, Zhang ZM, Xia Y et al. LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br. J. Cancer 109(4), 994-1003 (2013).
63. Yuan C, Li Z, Qi B, Zhang W, Cheng J, Wang Y. High expression of the histone demethylase LSD1 associates with cancer cell proliferation and unfavorable prognosis in tongue cancer. J. Oral Pathol. Med. 44(2), 159-165 (2014).
64. Derr RS, van Hoesel AQ, Benard A et al. High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer 14, 604 (2014).
65. Kahl P, Gullotti L, Heukamp LC et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66(23), 11341-11347 (2006).
66. Jerónimo C, Bastian PJ, Bjartell A et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 60(4), 753-766 (2011).
67. Cai C, He HH, Chen S et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20(4), 457-471 (2011).
68. Metzger E, Imhof A, Patel D et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 464(7289), 792-796 (2010).
69. Willmann D, Lim S, Wetzel S et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int. J. Cancer 131(11), 2704-2709 (2012).
70. Wu CY, Hsieh CY, Huang KE, Chang C, Kang HY. Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. Int. J. Cancer 131(6), 1423-1434 (2012).
71. Althoff K, Beckers A, Odersky A et al. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int. J. Cancer 133(5), 1064-1073 (2013).
72. Schulte JH, Lim S, Schramm A et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 69(5), 2065-2071 (2009).
73. Pollock JA, Larrea MD, Jasper JS, McDonnell DP, McCafferty DG. Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ER?-dependent and-independent manners. ACS Chem. Biol. 7(7), 1221-1231 (2012).
74. Cortez V, Mann M, Tekmal S et al. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 14(4), R108 (2012).
75. Quinlan KG, Verger A, Yaswen P, Crossley M. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim. Biophys. Acta 1775(2), 333-340 (2007).
76. Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4), 660-672 (2009).
77. Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128(3), 574-586 (2011).
78. Lv T, Yuan D, Miao X et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE 7(4), e35065 (2012).
79. Kruger R. Inhibition of LSD1 as a therapeutic strategy for the treatment of AML and SCLC. Presented at: 12th Annual Discovery on Target. Boston, MA, USA (10 October, 2014).
80. Low WC, Rujitanaroj PO, Lee DK et al. Nanofibrous scaffold-mediated REST knockdown to enhance neuronal differentiation of stem cells. Biomaterials 34(14), 3581-3590 (2013).
81. Sun G, Alzayady K, Stewart R et al. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol. Cell Biol. 30(8), 1997-2005 (2010).
82. Sun G, Ye P, Murai K et al. miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Nat. Commun. 2, 529 (2011).
83. Han X, Gui B, Xiong C et al. Destabilizing LSD1 by Jade-2 promotes neurogenesis: an antibraking system in neural development. Mol. Cell 55(3), 482-494 (2014).
84. Fuentes P, Cánovas J, Berndt FA, Noctor SC, Kukuljan M. RCOR1/LSD1 control the development of pyramidal cortical neurons. Cereb. Cortex 22(6), 1431-1441 (2012).
85. Zhang YZ, Zhang QH, Ye H et al. Distribution of lysinespecific demethylase 1 in the brain of rat and its response in transient global cerebral ischemia. Neurosci. Res. 68(1), 66-72 (2010).
86. Tan L, Zong C, Xie XS. Rare event of histone demethylation can initiate singular gene expression of olfactory receptors. Proc. Natl Acad. Sci. USA 110(52), 21148-21152 (2013).
87. Lyons DB, Allen WE, Goh T, Tsai L, Barnea G, Lomvardas S. An epigenetic trap stabilizes singular olfactory receptor expression. Cell 154(2), 325-336 (2013).
88. Zibetti C, Adamo A, Binda C et al. Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system. J. Neurosci. 30(7), 2521-2532 (2010).
89. Toffolo E, Rusconi F, Paganini L et al. Phosphorylation of neuronal lysine-specific demethylase 1 LSD1/KDM1A impairs transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2. J. Neurochem. 128(5), 603-616 (2014).
90. Rusconi F, Paganini L, Braida D et al. LSD1 neurospecific alternative splicing controls neuronal excitability in mouse models of epilepsy. Cereb. Cortex PMID: 24735673 (2014) (Epub ahead of print).
91. Shimojo M. Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued. J. Biol. Chem. 283(50), 34880-34886 (2008).
92. Zuccato C, Belyaev N, Conforti P et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 27(26), 6972-6983 (2007).
93. Soldati C, Bithell A, Johnston C, Wong KY, Stanton LW, Buckley NJ. Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington's disease. J. Neurochem. 124(3), 418-430 (2013).
94. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14(24), 3823-3835 (2005).
95. Kegel KB, Meloni AR, Yi Y et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277(9), 7466-7476 (2002).
96. Soldati C, Bithell A, Conforti P, Cattaneo E, Buckley NJ. Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease. J. Neurochem. 116(3), 415-425 (2011).
97. Charbord J, Poydenot P, Bonnefond C et al. High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. Stem Cells 31(9), 1816-1828 (2013).
98. Hockly E, Richon VM, Woodman B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100(4), 2041-2046 (2003).
99. Thomas EA, Coppola G, Desplats PA et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA 105(40), 15564-15569 (2008).
100. Conforti P, Zuccato C, Gaudenzi G et al. Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models. J. Neurochem. 127(1), 22-35 (2013).
101. Maes T. LSD1 inhibition: a new therapeutic approach in neurodegenerative disease. Presented at: Alzheimer's Drug Discovery Foundation Presymposium to the 3rd Clinical Trials on Alzheimer's Disease. Toulouse, France, 3 November 2010.
102. Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R. MeCP2 deficiency in the brain decreases BDNF levels by REST/RCOR1-mediated repression and increases TRKB production. Epigenetics 2(4), 214-222 (2007).
103. Cukier HN, Perez AM, Collins AL, Zhou Z, Zoghbi HY, Botas J. Genetic modifiers of MeCP2 function in Drosophila. PLoS Genet. 4(9), e1000179 (2008).
104. Ripke S, Sanders AR, Kendler KS et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43(10), 969-976 (2011).
105. Potkin SG, Macciardi F, Guffanti G et al. Identifying gene regulatory networks in schizophrenia. Neuroimage 53, 839-847 (2010).
106. Kim AH, Parker EK, Williamson V, McMichael GO, Fanous AH, Vladimirov VI. Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137. Schizophr. Res. 141(1), 60-64 (2012).
107. Wright C, Turner JA, Calhoun VD, Perrone-Bizzozero N. Potential Impact of miR-137 and Its Targets in Schizophrenia. Front. Genet. 4, 58 (2013).
108. Guella I, Sequeira A, Rollins B et al. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J. Psychiatr. Res. 47(9), 1215-1221 (2013).
109. Neelamegam R, Ricq EL, Malvaez M et al. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem. Neurosci. 3(2), 120-128 (2012).
110. Gupta-Agarwal S, Jarome TJ, Fernandez J, Lubin FD. NMDA receptor-and ERK-dependent histone methylation changes in the lateral amygdala bidirectionally regulate fear memory formation. Learn. Mem. 21(7), 351-62 (2014).
111. Maes T. LSD1/MAOB inhibitors as disease modifying drugs for Alzheimer's disease. Presented at: 14th International Conference on Alzheimer's Drug Discovery Conference Program. NJ, USA, 9-10 September 2013.
112. Maes T. Development of histone demethylase inhibitors for oncological and neurodegenerative disease. Presented at: 12th Annual Discovery on Target. Boston, MA, USA, 8-10 October 2014.
113. Maes T. Prospects of LSD1 inhibitors for the treatment of cancer and neurodegenerative disease. Presented at: 3rd Epigenetics in Drug Discovery Meeting. Boston, MA, USA, 8-10 May 2013.
114. Buesa C. ORY-1001, the first specific LSD1 inhibitor in acute myeloid leukemia therapy. Presented at: Epicongress. Boston, MA, USA, 22-24 July 2014.
115. Kruger RG, Mohammad H, Smitheman K et al. Inhibition of LSD1 as a therapeutic strategy for the treatment of acute myeloid leukemia. Presented at: 5th ASH Annual Meeting and Exposition. New Orleans, LA, USA, 7-10 December 2013.
116. Sankar S, Theisen ER, Bearss J et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin. Cancer Res. 20(17), 4584-4597 (2014).
117. Fiskus W, Sharma S, Shah B et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 14, 752 (2014).
118. Theisen ER, Gajiwala S, Bearss J, Sorna V, Sharma S, Janat-Amsbury M. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma. BMC Cancer 14, 752 (2014).
119. Dahnak D. From chemistry to the clinic: pathways for drug discovery and development, part 2: targeting epigenetics: an epicenter of oncology drug discovery. AACR Annual Meeting. Washington, DC, USA, 6-10 April 2013.
120. Jo S, Yarishkin O, Hwang YJ et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat. Med. 20(8), 886-896 (2014).
121. Buesa C. Development of epigenetic modulator, ORY-2001, for neurodegenerative disease. Presented at: 15th International Conference on Alzheimer's Drug Discovery. Jersey City, NJ, USA, 8-9 September 2014.